MIFH
UTHR icon

Migdal Insurance & Financial Holdings’s United Therapeutics UTHR Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,190
Closed -$176K – 774
2017
Q4 		$176K Sell
1,190
-212
-15% -$26.9K ﹤0.01% 326
2017
Q3 		$156K Buy
+1,402
New +$179K ﹤0.01% 326

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Migdal Insurance & Financial Holdings's UTHR Position: Q1 2018 in Review

Migdal Insurance & Financial Holdings sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 1,190 shares — an estimated $176K sold.

Migdal Insurance & Financial Holdings first reported a position in UTHR in Q3 2017 and held it in 2 quarters. The position peaked at $176K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

  • Migdal Insurance & Financial Holdings reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 1,190 United Therapeutics shares in Q1 2018, an estimated $176K.
  • Migdal Insurance & Financial Holdings first reported a position in United Therapeutics in Q3 2017 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's United Therapeutics position peaked at $176K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2018, filed 2 May 2018.